Manlio Fusciello

8PUBLICATIONS
38CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapyInnate immunityMolecular targetsApplied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jan 28, 2026
Leveraging glucan-induced trained immunity for the epigenetic and metabolic rewiring of macrophages to enhance colorectal cancer vaccine response.

Firas Hamdan, Sara Gandolfi, Federica D'Alessio

|Nov 12, 2025
Effect of extracellular vesicles in remodeling the tumor microenvironment by DNMT1 downregulation for enhanced cancer immunotherapy.

Salvatore Russo, Yvonne Giannoula, Sara Feola

|Mar 08, 2024
Novel peptide-based oncolytic vaccine for enhancement of adaptive antitumor immune response via co-engagement of innate Fcγ and Fcα receptors.

Sara Feola, Firas Hamdan, Salvatore Russo

|Nov 04, 2023
Development of mesothelioma-specific oncolytic immunotherapy enabled by immunopeptidomics of murine and human mesothelioma tumors.

Jacopo Chiaro, Gabriella Antignani, Sara Feola

|Sep 25, 2021
β2-Integrin Adhesion Regulates Dendritic Cell Epigenetic and Transcriptional Landscapes to Restrict Dendritic Cell Maturation and Tumor Rejection.

Carla Guenther, Imrul Faisal, Manlio Fusciello

|Aug 07, 2021
Novel oncolytic adenovirus expressing enhanced cross-hybrid IgGA Fc PD-L1 inhibitor activates multiple immune effector populations leading to enhanced tumor killing in vitro, in vivo and with patient-derived tumor organoids.

Firas Hamdan, Erkko Ylösmäki, Jacopo Chiaro

Pageof 2

Frequent Collaborators

8 joint publications

Vincenzo Cerullo

6 joint publications

Sara Feola

5 joint publications

Firas Hamdan

3 joint publications

Erkko Ylösmäki